Skip to main content
hero img

Significant median OS demonstrated in the VISION trial: 15.3 months with PLUVICTO + BSOC vs 11.3 months with BSOC alone (HR=0.62; 95% CI, 0.52-0.74; P<0.001)1,2

BSOC, best standard of care; HR, hazard ratio; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; PSMA+, prostate-specific membrane antigen positive.

1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 2. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322